Molecular basis of chemosensitivity of platinum pre-treated ovarian cancer to chemotherapy
Open Access
- 10 August 2010
- journal article
- Published by Springer Science and Business Media LLC in British Journal of Cancer
- Vol. 103 (5), 656-662
- https://doi.org/10.1038/sj.bjc.6605817
Abstract
Background: Methods: Results: Conclusion:Keywords
This publication has 26 references indexed in Scilit:
- Resistance gene expression determines the in vitro chemosensitivity of non-small cell lung cancer (NSCLC)BMC Cancer, 2009
- Yin Yang 1 Modulates Taxane Response in Epithelial Ovarian CancerMolecular Cancer Research, 2009
- A prospective randomized controlled trial of tumour chemosensitivity assay directed chemotherapy versus physician's choice in patients with recurrent platinum-resistant ovarian cancerAnti-Cancer Drugs, 2007
- The role of gene expression profiling in the clinical management of ovarian cancerEuropean Journal Of Cancer, 2006
- Genomic signatures to guide the use of chemotherapeuticsNature Medicine, 2006
- Effect of culture conditions on the chemosensitivity of ovarian cancer cell linesAnti-Cancer Drugs, 2006
- Micro-Array Analysis of Resistance for Gemcitabine Results in Increased Expression of Ribonucleotide Reductase SubunitsNucleosides, Nucleotides and Nucleic Acids, 2006
- Clonogenic assay with established human tumour xenograftsEuropean Journal Of Cancer, 2004
- Sequential single agents as first-line chemotherapy for ovarian cancer: a strategy derived from the results of GOG-132International Journal of Gynecologic Cancer, 2003
- Randomized Intergroup Trial of Cisplatin-Paclitaxel Versus Cisplatin-Cyclophosphamide in Women With Advanced Epithelial Ovarian Cancer: Three-Year ResultsJNCI Journal of the National Cancer Institute, 2000